

GLAXOSMITHKLINE PLC
Form 6-K
May 01, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2019

Commission File Number 001-15170

GlaxoSmithKline plc
(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-FX. . . . Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

GlaxoSmithKline plc (the 'Company')
Transaction notification

- 1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Philip Hampton
 - b) Position/status Non-Executive Chairman

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.68 | 2,790.179 |

Aggregated information

- d) Aggregated volume n/a (single transaction)
- Price
- e) Date of the transaction 2019-05-01
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr Vindi Banga
- b) Position/status Senior Independent Non-Executive Director

- c) Initial notification / amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent	
b) Nature of the transaction	Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	£15.68	458.386
d) Aggregated volume	n/a (single transaction)	
e) Date of the transaction	2019-05-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr Vivienne Cox
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent	
b) Nature of the transaction	Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	£15.68	338.807
d) Aggregated information	n/a (single transaction)	

Aggregated volume		
Price		
e) Date of the transaction	2019-05-01	
f) Place of the transaction	n/a	
1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Ms Lynn Elsenhans	
b) Position/status	Independent Non-Executive Director	
c) Initial notification / amendment	Initial notification	
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b) LEI	5493000HZTVUYLO1D793	
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a) Description of the financial instrument	American Depositary Shares ('ADSs')	
	ISIN: US37733W1053	
b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.	
c) Price(s) and volume(s)	Price(s) Volume(s)	
	\$40.67 1,174.570	
Aggregated information		
d) Aggregated volume	n/a (single transaction)	
Price		
e) Date of the transaction	2019-05-01	
f) Place of the transaction	n/a	
1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Dr Laurie Glimcher	
b) Position/status	Independent Non-Executive Director	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
- b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.
- | | Price(s) | Volume(s) |
|-----------------------------|--------------------------|-----------|
| c) Price(s) and volume(s) | \$40.67 | 1,351.687 |
| Aggregated information | | |
| d) Aggregated volume | n/a (single transaction) | |
| e) Date of the transaction | 2019-05-01 | |
| f) Place of the transaction | n/a | |

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr Jesse Goodman
- b) Position/status Independent Non-Executive Director
- c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.	
b) Nature of the transaction		
c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	\$40.67	407.837
d) Aggregated volume	n/a (single transaction)	
Price		
e) Date of the transaction	2019-05-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms Judy Lewent
b) Position/status	Independent Non-Executive Director
c) Initial notification / amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
--	---

b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.	
------------------------------	--	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	\$40.67	454.447

d) Aggregated volume	n/a (single transaction)	
Price		

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2019-05-01
- f) Place of the transaction n/a
-
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr Urs Rohner
- b) Position/status Independent Non-Executive Director
- c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2019 to 31 March 2019.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.68 | 458.386 |
- Aggregated information
- d) Aggregated volume n/a (single transaction)
- Price
- e) Date of the transaction 2019-05-01
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 01, 2019

By:/s/ VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for
and on
behalf of GlaxoSmithKline
plc